Exiqon
Home Search Contact Print Sign In
 
Products Services Resource Center Ordering About Exiqon
microRNA Research
mRNA & lncRNA Research
DNA Research
Custom LNA™ Oligos
LNA™ Phosphoramidites
RNA Isolation
Sequencing
Microarray Analysis
Real-time PCR
Northern Blotting
In Situ Hybridization
Functional Analysis
RNA Isolation
Sequencing
Microarray Analysis
Real-time PCR
In Situ Hybridization
Antisense
SNP Detection
Sequencing
Microarray Analysis
In Situ Hybridization
RNA Isolation Services
microRNA PCR Services
Sequencing Services
Custom Pharma Service
Documents
Application Stories
Movies
Contact
News
 

About Exiqon

Exiqon, a leading supplier of flexible solutions for RNA research, is now part of QIAGEN.

Exiqon, now a QIAGEN company


Exiqon and QIAGEN have joined forces to bring you an enriched product and service offering that builds on the expertise and product synergies of the two companies.

As of 1 October 2017, Exiqon products and services are fully integrated with QIAGEN, and available for purchase only through QIAGEN. This website will redirect you to the relevant pages on qiagen.com.

Products & Services

Exiqon's products and services are used by researchers in academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of disease. Taking advantage of our proprietary LNA™ technology, our product lines offer superior specificity and sensitivity for analysis of microRNA, mRNA and long non-coding RNA. Exiqon's products and services encompass the entire workflow from sample preparation to expression analysis (Sequencing, Array and qPCR), detection and functional analysis both in vitro and in vivo. Exiqon Services offers expertise in RNA Next Generation Sequencing, microRNA profiling and biomarker discovery from clinical samples.

By joining forces with QIAGEN, our products and services are now complemented by QIAGEN's global reach and powerful Sample to Insight® solutions. We continue to support your research with the dedication and expertise that you have come to expect from us.

Highlights

Exiqon A/S was founded on 1 November 1995 and became operational in the spring of 1996. At the end of 1997, Exiqon secured the exclusive rights to the LNA™ (Locked Nucleic Acid) technology from the Danish inventors of the technology. Exiqon developed the LNA™ technology, including procedures for large-scale manufacturing and a large number of applications for the LNA™ technology, which have all been patented.

In 1999, Cureon A/S was founded as a subsidiary of Exiqon for the purpose of exploiting the therapeutic potential of the LNA™ technology. Cureon A/S later merged with Panteco A/S, forming the company Santaris Pharma A/S. Exiqon has since sold its stake in Santaris Pharma A/S. Santaris Pharma A/S was acquired by F. Hoffmann-La Roche AG in 2014. Exiqon has retained all rights to the LNA™ technology, except for therapeutic applications.

In 2003, Exiqon developed and implemented the product oriented strategy for its Life Sciences division. The first research product, Universal ProbeLibrary™, was launched in the spring of 2004. In 2005, Exiqon formed a strategic alliance with Roche Diagnostics for selling the Universal ProbeLibrary™.

In 2006, Exiqon established a subsidiary in the United States and a US sales organization.

In June 2016, Exiqon was acquired by QIAGEN, bringing Exiqon's unique products and services into the QIAGEN portfolio.

In October 2017, Exiqon and QIAGEN officially joined forces when Exiqon products and services became fully integrated with QIAGEN, and available for purchase only through QIAGEN.

Technical Service

USA & Canada
+1 781 376 4150
Send email

All other countries
+45 45 65 09 29
Send email

Office Location

Exiqon A/S
Skelstedet 16
2950 Vedbaek
Denmark
+45 45 66 08 88
CVR/Tax ID: 18984431

Press & Media

Kim Sørensen
Vice President & General Manager
+45 45 66 08 88
  Privacy   Sitemap   Legal